Abstract: Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Abstract: The present invention relates to a use of drug conjugates for treating tumor diseases and method thereof. Specifically, the present invention provides the use of the bioactive molecule conjugate represented by Formula (I) in treating tumor diseases and method thereof, wherein the tumor diseases are particularly preferably unresectable locally advanced or metastatic solid tumors that are refractory to current standard treatment, especially non-small cell lung cancer.

Abstract: Provided are a macrocyclic drug conjugate, and a preparation method therefor and the use thereof. The macrocyclic drug conjugate has a structure as shown in formula Ab-[M-L-E-D]x. The antibody-drug conjugate has a good targeted killing effect on solid tumors such as gastric cancer, breast cancer, lung cancer and urothelial carcinoma.

Abstract: Provided are a macrocyclic compound and a preparation method and a use thereof, which has a structure shown in the formula M?-L-E-D. The compound can be used to prepare an antibody-drug conjugate. The conjugate has a relatively good drug-antibody conjugation ratio and has an excellent targeted killing effect on solid tumors such as gastric cancer, breast cancer, lung cancer, and urothelial carcinoma.

Abstract: A fused ring compound and a preparation method therefor and a use thereof. The compound has excellent therapeutic effect on solid tumors such as gastric cancer, breast cancer, lung cancer or urothelial cancer, or hematological malignancies.

Abstract: A compound having a biological activity, and a preparation method therefor and the use thereof. The compound has a structure as shown in formula M?-L-E-D, the compound can be used for preparing an antibody-drug conjugate. The conjugate has a better drug-to-antibody conjugation ratio, and also has a good targeted killing effect on solid tumors such as gastric cancer, breast cancer, lung cancer and urothelial carcinoma.

Abstract: Provided is the use of a compound of formula I, a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a metabolite or a prodrug thereof, or a composition thereof in the preparation of a drug for treating alopecia such as alopecia areata. An azetidine derivative has clear action mechanisms and pharmacodynamic effects, good pharmacokinetic properties and a good safety, which greatly improves the medication compliance of patients.

Abstract: The present invention relates to a camptothecin compound with anti-tumor activity, a preparation method therefor and use thereof. In particular, the present invention relates to a compound of the following formula or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method thereof and use thereof.

Abstract: The present invention relates to the field of disease treatment, and particularly relates to an anti-PTK7 antibody or antigen-binding fragment thereof, nucleic acid molecules encoding the same, and a method for preparing the same. The anti-PTK7 antibody or antigen-binding fragment thereof of the present invention has high affinity binding and endocytosis activity to PTK7, and meanwhile has good hydrophilicity. Therefore, the present invention further relates to use of the antibody or antigen-binding fragment thereof in disease treatment and diagnosis.

Abstract: A conjugate having a targeting effect, and a preparation method therefor and a use thereof. The conjugate has a structure shown in formula Ab-[M-L-E-D]x. A drug is selected from a DNA topoisomerase inhibitor. An antibody drug conjugate prepared has a better drug-to-antibody ratio, and has an excellent targeted killing effect on solid tumors such as gastric cancer, breast cancer, lung cancer and urothelial carcinoma.

Abstract: Provided are an antibody-drug conjugate, and a preparation method therefor and use thereof. The antibody-drug conjugate has a structure as shown in formula Ab-[M-L-E-D]x, the drug is selected from a tubulin inhibitor, and the prepared antibody-drug conjugate has a better drug antibody coupling ratio and has a good targeted killing effect on solid tumors such as gastric cancer, breast cancer, lung cancer and urothelial carcinoma.

Abstract: The present invention relates to a chemical coupling linker, and an antibody-drug conjugate prepared with the linker. The present invention further relates to a use of the antibody-drug conjugate in treating related disease of tumors, etc.

Abstract: Provided are use of a drug conjugate in treatment of a tumor disease and a method thereof. Specifically provided are use of a bioactive conjugate as shown in formula (I) for treating HR+/Her2? breast cancer and a method thereof. Formula (I):{D-[L1-(L2)m1-(L3)m2-(L4)m3-E]}?-A.

Abstract: The present application provides a preparation method for a nitrogen-containing fused ring compound having anti-tumor activity. According to the method, a target product can be efficiently obtained under relatively mild reaction conditions, and upon comparison with the original processes, the yield rate is remarkably improved, and the material cost is greatly reduced, thereby better facilitating process scale-up.

Abstract: The present application relates to the field of medicines, and in particular to an antibody-drug conjugate of a glucocorticoid receptor agonist. Specifically, the present application provides a glucocorticoid receptor agonist, which has good agonistic activity. The present application further provides a drug-linker compound for coupling, wherein the drug is a glucocorticoid receptor agonist. The present application further provides an antibody-drug conjugate prepared by coupling the drug-linker compound and the antibody, wherein the antibody-drug conjugate has good drug coupling uniformity, and has an excellent treatment effect on inflammatory diseases such as rheumatoid arthritis. The present application further provides a preparation method for the glucocorticoid receptor agonist and the antibody-drug conjugate thereof, and uses of the glucocorticoid receptor agonist and the antibody-drug conjugate thereof in the field of medicines.

Abstract: The present application provides a method for preparing a drug-linker conjugate. Specifically, the present application provides a method for preparing compound IM2, which comprises the following steps: adding compound SM1 to a mixed solution of triphosgene and 4-dimethylaminopyridine to obtain an intermediate solution; adding compound SM2 to the intermediate solution, stirring the mixture, thereby obtaining compound IM2. The stability, practicality and scalability of the process are improved by optimizing the preparation process of IM2 and using a normal chromatography purification method that is easily scalable.

Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.

Abstract: The present disclosure relates to an antibody-drug conjugate (ADC) for treating CDH3-positive cancer. The ADCs have a CDH3 antibody and a drug-linker molecule conjugated to the antibody. The ADC of the present disclosure has a better drug-antibody conjugation ratio and a good, targeted killing effect on CDH3-positive cancer. Also provided is a preparation method of the antibody-drug conjugate and use thereof in the treatment of the CDH3-positive cancer.

Abstract: The present application relates to an antibody-drug conjugate and a method for preparation and use thereof, and specifically relates to an antibody-drug conjugate for treating CEACAM5-positive cancer, including an anti-CEACAM5 antibody, and drug-linker molecules conjugated to the antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody has excellent binding activity to CEACAM5-positive cells, and can efficiently deliver drugs to CEACAM5-positive cells. In some embodiments, the drug includes a DNA topoisomerase inhibitor. The antibody-drug conjugate of the present application has a better drug-antibody conjugation ratio, and has a good targeted killing effect on certain cancers.

Abstract: The present invention belongs to the technical field of biomedicine, and relates to a method for treating cancer by using an antibody-drug conjugate. In particular, the present invention relates to a use of an antibody drug conjugate represented by formula (I) and a pharmaceutically acceptable salt, a stereoisomer or a metabolite thereof, or a solvate of the foregoing in the manufacture of a medicament for preventing and/or treating a HER2-expressing, amplified or mutated cancer, wherein A is a group obtained by removing n amino groups from an antibody against HER2 or an active fragment or variant thereof; preferably, A is trastuzumab or a group obtained by removing n amino groups from Pertuzumab; n is selected from 1-10, such as 2-10 or 2-8; and preferably, n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8.